Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3384541 A
Publication typeGrant
Publication dateMay 21, 1968
Filing dateOct 28, 1964
Priority dateOct 28, 1964
Publication numberUS 3384541 A, US 3384541A, US-A-3384541, US3384541 A, US3384541A
InventorsWilliam G Clark
Original AssigneeWilliam G. Clark
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Spermicidal vaginal pharmaceutical concentrate for producing nonaqueous foam with aerosol propellants
US 3384541 A
Abstract  available in
Images(4)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States Patent 3,384,541 SPERMICIDAL VAGINAL PHARMACEUTICAL CONCENTRATE FOR PRODUCENG NON- AQUEOUS FOAM WITH AEROSOL PROPEL- LANTS William G. Clark, 1142 Las Pulgas Road, Pacific Palisades, Calif. 90272 No Drawing. Filed Oct. 28, 1964, Ser. No. 407,231 1 Claim. (Cl. 167-58) ABSTRACT OF THE DISCLOSURE The invention provides a new composition of matter comprising a major proportion of propylene glycol in a minor proportion of an ethoxylated tallow alcohol, the composition being adapted to incorporation in foam-producing assemblies.

This invention relates to a new and useful non-aqueous foam-producing pharmaceutical substance, and more particularly to such a substance adapted for use as a medicant in a self-propelled dispenser using fluorinated hydrocarbons or other aerosol propellants.

There is a need for a simple, easily used single-dose contraceptive which can be applied as an aerosol foam into the vaginal canal. There has also been a need for a pharmaceutical vehicle for medicants adapted to be injected into human body cavities that can be used either with or without water, depending upon the stability of the ingredients to be incorporated into the preparation. Thus, it is desirable to have a single base that can be used with various enzymes, antibiotics, and medicinal agents, with or without spermicidal agents.

Accordingly, it is a primary object of the present invention to provide a newand useful non-aqueous foamproducing vehicle.

Another object of the invention is to provide a vehicle of the type described in combination with spermicidal substances.

Another object of the present invention is to provide a foam-producing vehicle that can be used either with or without water and various enzymes, antibiotics, and spermicidal agents.

Yet another object .of the present invention is to provide a new and useful non-aqueous foam-producing vehicle which contains ethoxylated tallow alcohol as a foaming agent, emulsifier, detergent, Wetting agent, and viscosity builder.

A further object of the present invention is to provide a vehicle of the type described which is also spermicidal.

A still further object of the present invention is to provide a vehicle of the type described which is especially suited for use in and in combination with aerosol type applicators for injecting medicants into human body cavities.

A medicinal application of this type is shown and claimed in copending application Ser. No. 407,170, filed Oct. 28, 1964, by the instant inventor, now abandoned.

The non-aqueous foam-producing pharmaceutical substance of the present invention includes a vehicle containing ethoxylated tallow alcohol as a foaming agent, emulsifier, detergent, wetting agent, and viscosity builder. The

3,384,541 Patented May 21, 1968 "ice ethoxylated alcohol is a condensate of pressure-hydrogenated tallow alcohol. The general formula is with R being a combination of CH (CH CH OH (stearyl alcohol 62%), CH (CH CH OH (cetyl alcohol 33%), and CH (CH CH OH (myristyl alcohol 5%) and the x ranging from three to eleven moles of ethylene oxide.

Propylene glycol U.S.P. may serve as a solvent, preservative, and emollient, and propylhydroxyparaben U.S.P. and methylhydroxyparaben U.S.P. are used as preservatives. In preparing the vehicle, grams of propylene glycol U.S.P'. are heated to approximately 50 degrees C. and 0.4 gram of methylhydroxyparaben plus 0.2 grain of propylhydroxyparaben are added and stirred. Two grams of ethoxylated tallow alcohol containing three moles of ethylene oxide, oil-soluble type, are heated to 50 degrees C., and combined with the propylene glycol preservative combination. Ethoxylated tallow alcohol containing from three to eleven moles of ethylene oxide may be used in this formula, depending upon the consistency of foam desired. The product is allowed to cool, and a sufficient amount of propylene glycol U.S.P. is added to make the product weigh 50 grams. Other glycols, as well as glycerol can be used in place of propylene glycol.

Spermicidal preparations are made from this vehicle, as described in the following examples, by dissolving the active ingredients in a sufiicient amount of propylene glycol U.S.P. to make 50 grams, and the resulting product is combined with 50 grams of the vehicle to make grams of spermicidal foam concentrate. In some cases, heat must be employed to effect solution. Heat labile substances must be added after cooling.

The non-ionic nature of the vehicle makes possible the addition of cationic or anionic substances without affecting the foam-producing and barrier action of the ingredients. Propylene glycol is an excellent solvent for many organic chemicals. Its solubility with water in all proportions makes possible the addition of aqueous solutions of spermicidal agents. This vehicle mixes quickly with seminal fluid and vaginal secretions, permitting rapid action of the active ingredients. Its surfactant action spreads the spermicide into all surfaces and crevices. The non-aqueous nature of the vehicle minimizes variations in action due to individual variations of moisture present. The viscous base and foam provide barrier action to passage of sperm through the cervix.

The vehicle itself is spermicidal as shown by the Sanderson-Cramer method of spermicidal evaluation. The vehicle, when diluted with two parts of buffered fructose solution, kills human sperm in twenty seconds. The buffered fructose solution contained three percent fructose, 0.24% anhydrous phosphate, 0.01% mono potassium phosphate, 0.2% sodium chloride, and distilled water (q.s.).

When diluted with an equal volume of propylene glycol U.S.P., the vehicle of the present invention produces a foam with propellants from an aerosol container of the types shown and described in said copending application. A partial emulsification results when the foam concentrate is shaken with fluorinated hydrocarbons or other aerosol propellants. When released in the manner described in said copending application, an excellent foam is produced. The ratio of vehicle to added propylene glycol can be altered to vary the foam consistency or to compensate for viscosities of added substances. Because of the insolubility of the ethoxylated tallow alcohols in water, the latter can be added to stiffen the foam where it does not affect the stability of added substances.

The formulation has been shown to be non-toxic to the mucosa of the human vagina and cervix. An amount in excess of that ordinarily used, namely grams of the liquid foam concentrate, was applied to the cervical mucosa of six oflice patients and examination made the next morning. No indications of inflammation were seen, even on repeated application.

The vehicle of the present invention is stable over long periods of time and maintains the stability of added ingredients which are unstable in aqueous vehicles of the prior art.

The following are typical examples of the non-aqueous foam-producing pharmaceutical substance of the present invention:

EXAMPLE 1 EXAMPLE 2 The product of Example 1 was prepared in the manner of Example 1 except that the ethoxylated tallow alcohol contained four moles of ethylene oxide.

EXAMPLE 3 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained five moles of ethylene oxide.

EXAMPLE 4 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained six moles of ethylene oxide.

EXAMPLE 5 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained seven moles of ethylene oxide.

EXAMPLE 6 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained eight moles of ethylene oxide.

EXAMPLE 7 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained nine moles of ethylene oxide.

EXAMPLE 8 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained ten moles of ethylene oxide.

EXAMPLE 9 The produce of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained eleven moles of ethylene oxide.

EXAMPLE 10 A product was prepared in accordance with each of the preceding examples except that, in each case, eighty grams 1 of glycerol USP were used in place of the propylene glycol.

EXAMPLE 11 Grams Aliphatic polyoxyethylene ether (100% active.

Made from commercial tridecyl alcohol and ethylene oxide to give material with an inverse cloud point of approximately 40-42 C. The material is made by standard ethoxylation technique) 5 The vehicle of Example 1 50 Propylene glycol q.s. ad 100 The aliphatic polyoxyethylene ether provides an excellent spermicide. Its non-ionic nature permits its combination with anionic or cationic agents without any change in spermicidal or antibiotic power. This composition produces an excellent foam when combined with propellants in aerosol containers. The ratio of propylene glycol to vehicle can be altered to produce varied consistency of foam.

EXAMPLE 12 Grams Aliphatic polyoxyethylene ether (100% active, de-

scribed in Example 11) 5 Lactic acid U.S.P. 0.5 Distilled water 10 Vehicle of Example 1 50 Propylene glycol U.S.P. q.s. ad

Sufiicient acid has been added to this product to produce a pH of 4.0 which increases the spermicidal power because it produces a condition resembling the vaginal pH of 4.5. Water has been added to aid in the ionization of the acid because the effect of acids in spermicides depends upon the extent to which they ionize.

EXAMPLE 13 Grams Aliphatic polyoxyethylene ether (100% active, de-

scribed in Example 11) 5 Papain 1 Vehicle of Example 2 50 Propylene glycol U.S.P. q.s. ad 100 EXAMPLE 14 Grams Aliphatic polyoxyethylene ether (100 active, de-

scribed in Example 11) 5 Trypsin 1 Vehicle of Example 3 50 Propylene glycol U.S.P. q.s. ad 100 Other pancreatic enzymes that could be used in the foam concentrate include cathepsins and chymotrypsin.

EXAMPLE l5 Grams Aliphatic polyoxyethylene ether of Example 11 5 Desoxyribonucleases (a Dornase proteolytic enzyme) 1 Vehicle of Example 4 50 Propylene glycol U.S.P. q.s. ad 100 Bacterial protease from B. Subtz'lis 1 Vehicle of Example 5 50 Propylene glycol U.S.P. q.s. ad 100 Other proteases from microbiological sources included those from Pseudomonas, Clostridia, and fungi. Hyaluronidase also has been used. The proteolytic enzymes described in Examples 13 through 16 enhance the mucolytic action upon sperm as well as vaginal and cervical mucous, allowing the spermicide to reach the sperm better. The cleansing and anti-inflammatory, antibioticenhancing, fibrinolytic, mucolytic, and debriding properties of such enzymes is known. Thus, they can be used in vehicles of the present invention for intravaginal infestations such as vaginitis, leukorrhea, trichomonas, moniliasis, as well as for hygienic and prophylactic purposes by incorporating them alone or in combination with suitable antiseptics, germicides, antibiotics, and peptizing agents such as carbamide. Water has been omitted in Examples 13 through 16 to increase the stability of the enzymes and antibiotics. Stability studies have shown that enzymes retain over 50% of their proteolytic activity against standard substrates when left at room temperature for six months.

Propylene glycol U.S.P. q.s. ad 100 This combination was formulated for instances where a contraceptive is desired in combination with trichomonal or other antibiotic or where the latter is desired alone in an aerosol foam treatment. It is known that Tyrothricin and Chlortetracycline are more active protozoal agents than streptomycin, chloramphenicol, or penicillin. Tyrothricin possesses many advantages over other antibiotics for use in the vehicle of the present invention. It is odorless and has remarkable stability, being stable in aqueous solutions and propylene glycol for long periods even at summer temperatures. Its solution in propylene glycol may be autoclaved without significant loss of activity. Its solubility in propylene glycol and its compatibility with many organic and inorganic substances makes it uniquely useful with a spermicidal composition. Lactic acid has been added to this composition to maintain a healthier flora in the vagina. As is known, the treatment of trichomonas vaginalis is directed toward cleanliness and maintenance of acid pH in the vagina. Water has been added to the formula to aid in the ionization of the acid.

EXAMPLE l8 Grams Aliphatic polyoxyethylene ether of Example 11 5 Tyrothricin 0.5 Papain 1 Vehicle of Example 7 50 Propylene glycol q.s. ad 100 can be expected in vivo that do not show in this test because of the enhanced action of the added enzymes and acids. No appreciable difference in spermicidal action was noted with the addition of antibiotics in vitro.

EXAMPLE 19 Grams Aliphatic polyoxyethylene ether of Example 11 5 Hydrocortisone alcohol, micronized 1 Vehicle of Example 8 50 Propylene glycol q.s. ad

Hydrocortisone can be used along with the contraceptive when its anti-inflammatory action is desired. The relative insolubility and its high degree of activity of the alcohol form make it useful, especially where the systemic effects of the glucocorticoid are not desired.

EXAMPLE 20 Grams Aliphatic polyoxyethylene ether of Example 1 5 Hydrocortisone alcohol, micronized 1 Neomycin sulfate, micronized 0.5 Vehicle of Example 1 50 Glycerol q.s. ad 100 This formula combines the anti-inflammatory qualities of Hydrocortisone with the anti-pyogenic action of neomycin plus contraceptive.

EXAMPLE 21 Grams Aliphatic polyoxyethylene ether of Example 11 5 Sulfanilamide, micronized 10 Vehicle of Example 1 50 Propylene glycol q.s. ad 100 Other sulfonamides may be used in place of the sulfanilamide or a combination of two or more may be used. This formula is useful in the post-operative care of the cervix and for secondary invasions of trichomonas vaginalis.

EXAMPLE 22 Grams Aliphatic polyoxyethylene ether of Example 11 5 Sulfanilamide, micronized 10 Neomycin sulfate, micronized 0.5 Vehicle of Example 1 50 Propylene glycol U.S.P. q.s.d. ad 100 This formula can be used when the action of a sulfonamide along with an antibiotic is desired plus contraceptive. Another sulfonamide or sulfonamides may be used as well as antibiotics.

EXAMPLE 23 Grams Aliphatic polyoxyethylene ether of Example 11 5 Povidone iodine NND 1 Vehicle of Example 1 50 Propylene glycol q.s. ad 100 The addition of the iodine compound aids in the treatment of non-specific vaginitis and Candida albicans, Monilia, and T richomonas vaginalis along with a contraceptive.

EXAMPLE 24 Examples were prepared in accordance with each of the thirteen preceding examples (ll-23) execept that in each case the aliphatic polyoxyethylene ether was omitted.

While the particular embodiments of the present invention herein described in detail are fully capable of attaining the objects and providing the advantages hereinbefore stated, it is to be understood that they are merely illustrative of the presently preferred embodiments of the invention and that no limitations are intended to the specific embodiments herein described other than as defined in the appended claim.

I claim:

1. A spermicidal vaginal pharmaceutical concentrate for producing non-aqueous foam with aerosol propellants comprising:

80 grams of propylene glycol;

0.4 gram of methylhydroxyparaben;

0.2 gram of propylhydroxyparaben; I

2 grams of ethoxylated tallow alcohol containing from three to eleven moles of ethylene oxide of the oilsoluble type; said composition of matter being nonaqueous, thereby constituting a stable vehicle for proteolytic enzymes and antibiotics.

References Cited UNITED STATES PATENTS 2,854,377 9/1958 Elias 16758 2,943,979 7/1960 Elias 167-58 3,055,834 9/1962 Charle et a1. 25290 8 3,131,152 4/1964 Klausner 252-305 3,219,525 11/1965 Berkow 167-58 3,240,396 3/ 1966 Friedenberg 222-146 3,244,589 4/ 1966 Sunnen et a1 167-58 OTHER REFERENCES McCutcheon, John W.: D & E, 1963, Detergents and Emulsifiers, 1963, Annual pub., 1963, Morristown, N.J., pp.: cover, inside front cover, 31, 33, 45, 57, 58, 62, 63, 86, 87, 112, 116, 131, 135.

Federal Register 30 (228): 14639 Nov. 25, 1965, Dimethyl Sulfoxide (DMSO) Preparations, Termination of Clinical Testing and Investigational Use.

Ferm: Teratogenic Efiect of Dimethyl Sulphoxide, Lancet, I, 1966, pp. 208-209, Jan. 22, 1966.

LEWIS GOTTS, Primary Examiner.

SHEP K. ROSE, Examiner.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2854377 *Sep 22, 1955Sep 30, 1958Nathaniel M EliasEffervescent compositions containing a surface active agent
US2943979 *Jun 23, 1959Jul 5, 1960Nathaniel M EliasConcentrated foam-producing spermicides
US3055834 *Jun 2, 1958Sep 25, 1962OrealAnhydrous anion-active detergents in the form of aerosols
US3131152 *Jun 13, 1960Apr 28, 1964Allied ChemFoam producing formulations
US3219525 *Jan 16, 1963Nov 23, 1965Menlo Park Lab IncVaginal douche solution
US3240396 *Jun 11, 1963Mar 15, 1966Robert M FriedenbergAerosol dispenser
US3244589 *Oct 26, 1962Apr 5, 1966SunnenAlkyl phenoxy polyethoxy ether spermicidal aerosol
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3819528 *Mar 6, 1972Jun 25, 1974Procter & GambleStabilized aqueous enzyme compositions
US3929985 *Jan 18, 1974Dec 30, 1975Richardson Merrell IncAnhydrous candicidin foam compositions
US4252787 *Dec 27, 1976Feb 24, 1981Cambridge Research And Development GroupAnti-fertility composition and method
US4310510 *Oct 3, 1980Jan 12, 1982Sherman Kenneth NSelf administrable anti-fertility composition
US4551148 *Oct 11, 1984Nov 5, 1985Kv Pharmaceutical CompanyVaginal delivery systems and their methods of preparation and use
US5266329 *Oct 31, 1985Nov 30, 1993Kv Pharmaceutical CompanyVaginal delivery system
US5340836 *Jun 1, 1992Aug 23, 1994Mark S. ReinhardComposition and method for treatment of vaginal yeast infections
US5573765 *Aug 13, 1994Nov 12, 1996Mark S. ReinhardComposition and method for treatment of vaginal yeast infections
US7700076Aug 20, 2004Apr 20, 2010Foamix, Ltd.Penetrating pharmaceutical foam
US7704518May 9, 2006Apr 27, 2010Foamix, Ltd.Foamable vehicle and pharmaceutical compositions thereof
US7820145Apr 28, 2004Oct 26, 2010Foamix Ltd.Oleaginous pharmaceutical and cosmetic foam
US8114385Dec 26, 2006Feb 14, 2012Foamix Ltd.Oleaginous pharmaceutical and cosmetic foam
US8119106Jul 8, 2009Feb 21, 2012Foamix LtdFoamable iodine compositions
US8119109Mar 13, 2007Feb 21, 2012Foamix Ltd.Foamable compositions, kits and methods for hyperhidrosis
US8119150Jul 6, 2006Feb 21, 2012Foamix Ltd.Non-flammable insecticide composition and uses thereof
US8343945Jun 7, 2010Jan 1, 2013Foamix Ltd.Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8362091Apr 26, 2010Jan 29, 2013Foamix Ltd.Foamable vehicle and pharmaceutical compositions thereof
US8435498Apr 1, 2010May 7, 2013Foamix Ltd.Penetrating pharmaceutical foam
US8486374Jan 14, 2008Jul 16, 2013Foamix Ltd.Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8486375Feb 20, 2012Jul 16, 2013Foamix Ltd.Foamable compositions
US8486376Apr 6, 2005Jul 16, 2013Foamix Ltd.Moisturizing foam containing lanolin
US8512718Feb 12, 2010Aug 20, 2013Foamix Ltd.Pharmaceutical composition for topical application
US8518376Oct 6, 2009Aug 27, 2013Foamix Ltd.Oil-based foamable carriers and formulations
US8518378Sep 14, 2010Aug 27, 2013Foamix Ltd.Oleaginous pharmaceutical and cosmetic foam
US8618081May 4, 2011Dec 31, 2013Foamix Ltd.Compositions, gels and foams with rheology modulators and uses thereof
US8636982Aug 7, 2008Jan 28, 2014Foamix Ltd.Wax foamable vehicle and pharmaceutical compositions thereof
US8703105Mar 11, 2013Apr 22, 2014Foamix Ltd.Oleaginous pharmaceutical and cosmetic foam
US8709385Jul 14, 2010Apr 29, 2014Foamix Ltd.Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8722021Mar 6, 2013May 13, 2014Foamix Ltd.Foamable carriers
US8741265Mar 4, 2013Jun 3, 2014Foamix Ltd.Penetrating pharmaceutical foam
US8795635May 12, 2010Aug 5, 2014Foamix Ltd.Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8795693Nov 29, 2007Aug 5, 2014Foamix Ltd.Compositions with modulating agents
US8840869Apr 28, 2005Sep 23, 2014Foamix Ltd.Body cavity foams
US8865139Jul 9, 2014Oct 21, 2014Foamix Pharmaceuticals Ltd.Topical tetracycline compositions
US8871184Oct 1, 2010Oct 28, 2014Foamix Ltd.Topical tetracycline compositions
US8900553Jun 7, 2010Dec 2, 2014Foamix Pharmaceuticals Ltd.Oil and liquid silicone foamable carriers and formulations
US8900554Feb 20, 2012Dec 2, 2014Foamix Pharmaceuticals Ltd.Foamable composition and uses thereof
US8945516Oct 1, 2010Feb 3, 2015Foamix Pharmaceuticals Ltd.Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US8992896Aug 27, 2014Mar 31, 2015Foamix Pharmaceuticals Ltd.Topical tetracycline compositions
EP1495758A2 *Jan 7, 2000Jan 12, 20053M Innovative Properties CompanyFormulations and methods for treatment of mucosal associated conditions with an immune response modifier
WO1987002576A1 *Oct 31, 1985May 7, 1987Kv Pharm CoVaginal delivery systems
WO1998019545A1 *Nov 6, 1996May 14, 1998Mark S ReinhardComposition and method for the treatment of vaginal yeast infections
WO2005105090A1 *May 3, 2005Nov 10, 2005Aq & PlcCompositions for progeny gender control
Classifications
U.S. Classification424/45, 424/94.64, 424/94.3, 424/94.6, 424/94.65, 424/672, 514/967, 514/179, 514/957
International ClassificationA61K9/12, A61K9/00, C09K3/30
Cooperative ClassificationC09K3/30, A61K9/122, Y10S514/967, Y10S514/957, A61K9/0034
European ClassificationC09K3/30, A61K9/12B, A61K9/00M8